form13d.htm

0001411686-08-000254.txt : 20081112 0001411686-08-000254.hdr.sgml : 20081111 20081112130302 ACCESSION NUMBER: 0001411686-08-000254 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20081112 DATE AS OF CHANGE: 20081112 GROUP MEMBERS: HEALTHINVEST GLOBAL LONG/SHORT FUND SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIO IMAGING TECHNOLOGIES INC CENTRAL INDEX KEY: 0000822418 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 112872047 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-52563 FILM NUMBER: 081179723 BUSINESS ADDRESS: STREET 1: 826 NEWTOWN-YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940-1721 BUSINESS PHONE: 2677571360 MAIL ADDRESS: STREET 1: 826 NEWTOWN-YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940-1721 FORMER COMPANY: FORMER CONFORMED NAME: WISE VENTURES INC DATE OF NAME CHANGE: 19911023 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Healthinvest Partners AB CENTRAL INDEX KEY: 0001381843 IRS NUMBER: 000000000 STATE OF INCORPORATION: V7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: ARSENALSGATAN 4 CITY: STOCKHOLM STATE: V7 ZIP: SE-111 47 BUSINESS PHONE: 46 08 440 38 31 MAIL ADDRESS: STREET 1: ARSENALSGATAN 4 CITY: STOCKHOLM STATE: V7 ZIP: SE-111 47 SC 13D 1 form13d.htm SCHEDULE 13D FILED BY HEALTHINVEST PARTNERS AB 11-12-2008 form13d.htm

OMB APPROVAL

OMB Number: 3235-0145

Expires: February 28, 2009

Estimated average burden

Hours per response 14.5

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO

FILED PURSUANT TO §240.13d-2(a)

(Amendment No. _)*

Bio-Imaging Technologies, Inc.

-------------------------------------------------------------------------------

(Name of Issuer)

Common Stock

-------------------------------------------------------------------------------

(Title of Class of Securities)

09056N103

----------------------------------------

(CUSIP Number)

Healthinvest Partners AB

Arsenalsgatan 4

SE-111 47 Stockholm

Sweden

Tel. 011-46-8-440-38-31

With a copy to:

Stephen P. Wink, Esq.

Cahill/Wink LLP

5 Penn Plaza

23rd Floor

New York, NY 10001

(646) 378-2105

-------------------------------------------------------------------------------

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

November 12, 2008

-------------------------------------------------------------------------------

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule

because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

Page 1 of 7

------------------------------------------------
CUSIP No. 09056N103
------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------
1 Name of Reporting Persons
Healthinvest Partners AB

------------------------------------------------------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [X]
------------------------------------------------------------------------------------------------------------------------------
3 SEC Use Only
------------------------------------------------------------------------------------------------------------------------------
4 Source of Funds (See Instructions)
WC
------------------------------------------------------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)[ ]
------------------------------------------------------------------------------------------------------------------------------
6 Citizen or Place of Organization
Sweden
------------------------------------------------------------------------------------------------------------------------------

Number of 7 Sole Voting Power 756,893
------------------------------------------------------------------------------------------------------------------------------
Shares
Beneficially 8 Shared Voting Power 0
------------------------------------------------------------------------------------------------------------------------------
Owned by
Each 9 Sole Dispositive Power 756,893
------------------------------------------------------------------------------------------------------------------------------
Reporting
Person With: 10 Shared Dispositive Power 0
------------------------------------------------------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person

756,893
------------------------------------------------------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) [ ]
------------------------------------------------------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11)

5.3%
------------------------------------------------------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)

IA, HC
------------------------------------------------------------------------------------------------------------------------------

Page 2 of 7

------------------------------------------------
CUSIP No. 09056N103
------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------
1 Name of Reporting Persons
HealthInvest Global Long/Short Fund
------------------------------------------------------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [X]
------------------------------------------------------------------------------------------------------------------------------
3 SEC Use Only
------------------------------------------------------------------------------------------------------------------------------
4 Source of Funds (See Instructions)
WC
------------------------------------------------------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)[ ]
------------------------------------------------------------------------------------------------------------------------------
6 Citizen or Place of Organization
Sweden
------------------------------------------------------------------------------------------------------------------------------

Number of 7 Sole Voting Power 0
------------------------------------------------------------------------------------------------------------------------------
Shares
Beneficially 8 Shared Voting Power 756,893
------------------------------------------------------------------------------------------------------------------------------
Owned by
Each 9 Sole Dispositive Power 0
------------------------------------------------------------------------------------------------------------------------------
Reporting
Person With: 10 Shared Dispositive Power 756,893
------------------------------------------------------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person

756,893
------------------------------------------------------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) [ ]
------------------------------------------------------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11)

5.3%
------------------------------------------------------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)

OO
---------------------------------------------------------------------------------------------------------------------------------

Page 3 of 7

Item 1 Security and Issuer

The class of equity to which this statement relates is the common stock, $0.00025 par value (the “Common Stock”), of Bio-Imaging Technologies, Inc. (the “Company”), which has its principal executive offices at:

826 Newtown-Yardley Road

Newtown, Pennsylvania 18940-1721

Item 2 Identity and Background

The names of the persons filing this statement are Healthinvest Partners AB, a Swedish corporation, and HealthInvest Global Long/Short Fund, a specialty fund organized pursuant to the Swedish Mutual Funds Act (each, a “Reporting Person”).

Healthinvest Partners AB and HealthInvest Global Long/Short Fund are engaged in the business of investment management. Healthinvest Partners AB is the investment advisor and control person of Healthinvest Global Long/Short Fund, a security holder of the issuer.

The address of the principal office of each of the Reporting Persons is Arsenalsgatan 4, SE-111 47 Stockholm, Sweden.

During the last five years, neither of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3 Source and Amount of Funds or Other Consideration

The Reporting Persons acquired the 756,893 shares of Common Stock to which this Statement relates with investment capital held by HealthInvest Global Long/Short Fund as follows:

(a) HealthInvest Global Long/Short Fund acquired 756,893 shares of Common Stock on the open market between November 6, 2006 and November 10, 2008 for a total consideration of $3,700,832.

The above amount of total consideration includes any commissions incurred in making the investments. The source of these funds was the investment capital of the Reporting Persons, which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business.

Page 4 of 7

Item 4 Purpose of Transaction

All of the shares of Common Stock reported herein were acquired for investment purposes, and were originally acquired without the purpose or effect of changing or influencing control of the Company. The Reporting Persons review on a continuing basis the investment in the Company. Based on such review and depending on the price and availability of the Company's securities, the Reporting Persons may acquire, or cause to be acquired, additional securities of the Company, in the open market or otherwise, dispose of, or cause to be disposed of, securities of the Company, in the open market or otherwise, at any time, or formulate other purposes, plans or proposals regarding the Company or any of its securities, to the extent deemed advisable in light of general investment and policies of the Reporting Persons, the Company's business, financial condition and operating results, general market and industry conditions or other factors.

As part of the ongoing evaluation of this investment and investment alternatives, the Reporting Persons and their affiliates may consider any or all of the following: (a) the acquisition by any person of additional securities of the Company, or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries; (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board of directors; (e) any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company's business or corporate structure; (g) changes in the Company's charter or bylaws or other actions which may impede the acquisition of control of the Company by any person; (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above.

In addition, from time to time, the Reporting Persons and their affiliates may hold discussions with the Company regarding the matters described in subparagraphs (a) through (j) above.

On November 12, 2008, Anders Hallberg, the Managing Director and CEO of Healthinvest Partners AB, sent a letter to the Chairman of the Board of Directors of the Company and the Company’s Chief Executive Officer expressing, among other things, displeasure with the Company’s deteriorating shareholder value during 2008 and, in particular, the Company’s continued operation of the poorly performing CapMed division. Mr. Hallberg urged the Board and management of the Company to dispose of the CapMed division through divestiture or shutdown. A copy of such letter is attached hereto as Exhibit 99.2 and incorporated by reference herein.

Item 5 Interest in Securities of the Issuer

(a) As of the close of business on November 11, 2008, Healthinvest Partners AB and HealthInvest Global Long/Short Fund were the beneficial owners of 756,893 shares of Common Stock, which constitute in the aggregate 5.3% of the outstanding shares of Common Stock of the Company, based on 14,341,403 shares of Common Stock outstanding as reported on the Form 10-Q for the quarterly period ending September 30, 2008 filed by the Company.

(b) Healthinvest Partners AB has the sole power to vote, direct the voting of, dispose of and direct the disposition of the Common Stock owned by it as described in Item 5(a) above.

HealthInvest Global Long/Short Fund has shared power to vote, direct the vote of, dispose of and direct the disposition of the Common Stock owned by it as described in Item 5(a) above. Such power is shared with Healthinvest Partners AB.

(c) Transactions in the Common Stock by the Reporting Persons effected in the last 60 days are as set forth in the table below. All such trades were made in open market transactions.

Entity	Trade Date	Activity	Quantity	Average Price

HealthInvest Global Long/Short Fund	09/15/08	BUY	27,800	7.69
HealthInvest Global Long/Short Fund	09/19/08	BUY	25,000	7.71
HealthInvest Global Long/Short Fund	09/29/08	BUY	8,300	7.14
HealthInvest Global Long/Short Fund	09/30/08	BUY	30,000	7.43
HealthInvest Global Long/Short Fund	10/06/07	BUY	10,000	6.00
HealthInvest Global Long/Short Fund	10/06/08	BUY	10,000	6.00
HealthInvest Global Long/Short Fund	10/13/08	BUY	10,000	5.80
HealthInvest Global Long/Short Fund	10/15/08	BUY	60,000	5.66
HealthInvest Global Long/Short Fund	10/24/08	BUY	25,000	5.01
HealthInvest Global Long/Short Fund	10/30/08	BUY	10,000	4.08
HealthInvest Global Long/Short Fund	10/31/08	BUY	25,000	4.10
HealthInvest Global Long/Short Fund	11/07/08	BUY	97,806	2.56
HealthInvest Global Long/Short Fund	11/07/08	BUY	3,900	2.67
HealthInvest Global Long/Short Fund	11/10/08	BUY	100,000	2.81

Page 5 of 7

(d) The Reporting Persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock owned by them.

(e) Not applicable.

Item 6 Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

None.

Item 7 Material to be Filed as Exhibits

99.1 Joint Filing Agreement

99.2 Letter dated November 12, 2008 from Anders Hallberg, Managing Director and CEO of Healthinvest Partners AB, to the Chairman of the Board of Directors of the Company and the Company’s Chief Executive Officer.

Page 6 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE: November 12, 2008

HEALTHINVEST PARTNERS AB

By: /s/ ANDERS HALLBERG

Name: Anders Hallberg

Title: Managing Director and CEO

HEALTHINVEST GLOBAL LONG/SHORT FUND

By: /s/ ANDERS HALLBERG

Name: Anders Hallberg

Title: CEO of Managing Company

Page 7 of 7

EX-99.1 2 ex991.htm JOINT FILING AGREEMENT ex991.htm

Exhibit 99.1

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13D filed herewith (and any amendments thereto), relating to the common stock, $0.00025 par value, of Bio-Imaging Technologies, Inc., is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, on behalf of each such person.

November 12, 2008

HEALTHINVEST PARTNERS AB

By: /s/ ANDERS HALLBERG

Name: Anders Hallberg

Title: Managing Director and CEO

HEALTHINVEST GLOBAL LONG/SHORT FUND

By: /s/ ANDERS HALLBERG

Name: Anders Hallberg

Title: CEO of Managing Company

EX-99.2 3 ex992.htm LETTER TO BIO-IMAGING TECHNOLOGIES, INC. ex992.htm

Exhibit 99.2

David E. Nowicki, Chairman of the Board

and

Marl L. Weinstein, President and Chief Executive Officer

Bio-Imaging Technologies, Inc.

826 Newtown-Yardley Road

Newtown, PA 18940

November 12, 2008

Dear Messrs. Nowicki and Weinstein:

Healthinvest Partners AB and Healthinvest Global Long/Short Fund beneficially own, in the aggregate, approximately 5.3 percent of the outstanding common stock of Bio-Imaging Technologies, Inc. (the “Company”), making us the second largest shareholder of the Company.

We are very frustrated with the recent performance of the Company that has resulted in a deterioration of shareholder value in 2008. Although the Imaging Services division, which has grown 19 percent, and the newly acquired Phoenix Data Systems unit seem to be developing well, the Company’s share price has declined a catastrophic 66% year-to-date.

We believe that the source of the problem lies in the CapMed division. Despite allocating large resources to this loss-making unit for several years, significant revenues have failed to materialize. For example, in the most recent quarter, the division posted revenues of a mere $11,000 despite incurring approximately $776,000 in operating expenses. If the Company had sold CapMed to a third party or closed it down before the start of this year, the Company’s operating earnings for the first nine months in 2008 would have been around 43 percent higher without significant impact on revenues.

CapMed is an expensive development project with no synergies with Imaging Services and Phoenix Data Systems. If CapMed cannot be sold, it should be closed down. While the decision to divest or close a division is always difficult, it should now be evident to the Company’s Board and senior management that CapMed is having a significant, negative impact on shareholder value, which should be the Board’s highest priority. Surely, the Company’s Board and senior management agree that it is imperative that investor confidence in the Company not be undermined any further. Committing to either divest CapMed or close it down before the end of 2008 would go a long way in this direction.

We would like to schedule a call with both of you within the next week to take place no later than November 21, 2008 in order to discuss the issues and proposals raised in this letter. Please contact me with your availability. I look forward to hearing from you.

Sincerely,

Anders Hallberg

CEO and Managing Director

Healthinvest Partners AB

Arsenalsgatan 4, SE-111 47 STOCKHOLM

Tel: +46 (0)8 440 38 30 Fax: +46 (0)8 440 38 39

info@healthinvest.se, www.healthinvest.se

GRAPHIC 4 logo.jpg HEALTHINVEST PARTNER LOGO begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`! M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@`````` M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`#(` MQ`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/>?^"WW_!/#]FK0_P#@I5_P3R3PCX5N_!T'[?'[0D_AO]H6VT35 M]2>#7]9\0_&[X4Z=XH\;Z9'J-S>-H?B7Q':_%O6GU4Z3)9Z4]UI]A?6NFVM_ M)J5U?_V`?"S]G/X,_!/X+:3^SM\+?`.B^$/@OHFBZ_X?T[P#92:C=:3%I/BJ M_P!7U3Q):RSZE>7NIW9UO4M>UF_U.YO+^XN[N[U*[GEGWR;J_F\_X.![WQCI MO[>?_!$_4OAWH6D>*/B!8?M#ZM>^!O#6OZQ)X=T+Q#XPM/C)^R_/X:T/6O$$ M5AJDFA:3J^LI8Z?J.L1Z;J$FF6=S->I971@$+_JI_P`+M_X+#_\`1BO[)O\` MXF)XA_\`G*U^W<3RSS/^!/#*-7/,-[&CEN<3=+-,\PN"E.OA<^QN$PU>-+&8 MFE*L\/A*<,-2K6DZ5.,J4913E%_!Y6L!EV?<3N&!J<\L3@XJ6%P52LHTZN#H MU:L&Z5-J'M*LG4E"Z4I6DT]+?S'6?_!-S]DR;_@XSO/V/1\-+9?V9=+TA?B( MWPFDUOQ/-I%S=-^S=;_$--"_M8:W#X@AT"'X@W\.OC36U6XLYM/M6\+W%M+H M-R]HG]W>CZ18:#I>FZ)I-K!8:3H]A9Z5IFGVR[+:QT[3K9+2QM+=#RD-O;11 M0QID[50#)ZU_&O\`LYZ]\:_$G_!SQ-J_[0G@#P?\,/BM<_"K4UU_P9X$\:S_ M`!"\,:9;0?LM6$&BRV'BRZT+PY<:C)J&B1V-_>1R:1;&RO+BXLE:=+<7$O\` M8OXS\8^%OAYX1\4^/?'&OZ7X5\%^"?#FM^+O%WB?6[N*PT;PYX8\.:;=:QKV MNZO?3,L-GIFDZ797=_?W6:1E5":X/%O'YKB:G`^&S+,JN8>QX#R. MJY?7?KN'J8FK4QL*^+IUH5*E*O5KQHTHU<3&4I5E3AS3ERHZ>#:&%IT\\JX? M#1H.>>XZ"3H^QJ*C!4I4J4H-*4(T^>35-V47)V2.EHK\$KG_`(+T?#;1OA1X M;_:Y\5_L<_M?^%/^">'B[QW;>#-&_;AU?P_\-I?!L6CZGXJN?!?A_P"+NO?! M?3?B)>_M#>&O@KXEUZVC30O&VL?#6UO=0M=4\/&+PY_:'B+1]+N_V/\`B_\` M'CX3?`CX*^//VA_BEXUTOPQ\'/AMX$U;XD^+?'!^TZKIUGX.T?2WU>?5;"#1 M8-1O]>DO+18UT33=!M-2U3Q!>W-EIVAV6H7]]:6TWY`O2Q]F>O5R_C3QMX.^ M&_A/Q'X]^(7BOPUX$\"^#M%U'Q)XN\:>,M>TOPOX3\*^'M(MI;W5=>\2>(]; MNK'1]#T72[.&6[U'5=3O+6QL;6*2XN9XHHV&OA-\,/A'^U%\> M?V&_VO\`X+?L/?&K5?A_;>$_VK_$;_`/Q1H6A^'OBK;1WWP\^('Q'^%7PZ^- M'C'XN>`O`GB+3I[2_&IZGX4EU:S&HZ7I4VA?\))JNFZ'>?NFZ:?K.G.CI9ZG MIFIV;(R.L%[8W]A>0D%71Q+;75I=02T/PWXDU;1-.U/5-, MTVU\06\&A^+_``WJ,.O>'9-5\.W\.JQ+I^K74L-U'!]$W&L:59ZCIVD76I6% MMJNKK>/I6FW%Y;0W^IIIT<4VH/I]G)(MQ>I8Q3PRWK6T#?#.BVL5CH_AOPK MX6TOX):%X>T'2;.!4AL],TC2+&TT^QM846*WM;>*&-0B`5XQ^TY^WO\`M,6W M_!>']EC]GS3OV&/BUXFT;X+?LW?M1_$#P-H/ACXH?LY)XW^/>D?$C6M(\`1? M%G1AXN^,/A;P3X-\`Z#!\*M0_L31/&7C+0_B;J'_``D.I3ZMX)T[[/I]NP!_ M1S\9/C?\'_V=_A[K_P`6?CO\3O`GP>^&/A9+1_$'CWXD>*M&\'>%=+?4+N'3 M],MKC6M=O+*R^WZMJ5S:Z7H^FQROJ&L:K=VFEZ9:W=_=VUO+A?LX_M(?!/\` M:X^#/@_]H3]G7QY8_$WX.>/G\2Q^#_'&F:=KNDV&N'PAXNU[P+XB:UL?$NE: M+K,<>G^*O#&N:5YUSIL$5VUB;RQ>ZT^XM;N?:N/#^A_'3X,GP[\9/A4MKH7Q M7^'<&G_$KX+_`!(C\*>*'TVR\8^'XE\4_#CQJ/#FK>*?!>NW6EB_O/#VN2^' M=>\0^&[ZZMKB;1=9U33GM+^;^1__`((-_P#!2F3X,?\`!'']EWX3?`C]D+]J M?]M?X@_!?PK^TKXJ^.MM\`/"_AC3_!?P?M3^TC\7?'.F>%->^(/Q,\4^"?#_ M`(L^+?B3P7XIT/Q?X<^#7PO?QW\1[[PYJ%GJ=YH&FPZMH(U8W5P/[-:_D#_X M.G_V3O@7H7P5^&W[8FA^"K?1_C]XN^/_`(-^$OC/QEI]Y>0CQCX0N?A%\1-0 ML8O$>F&5["^U/0?^%;>';#1-5CAMKNVTH7FGSO=0RVWV/^CC]@S]M_X+?\%$ M?V7?AM^U=\!)/$4?@'XB0:O`-%\8:;!I/B[PKXB\-ZO>:!XF\+>);"SO=3T] M-5T;6+"Y@:XTO4]2TG4K0VNIZ5J%WI]Y;3O^*O\`P=:?\H]O@Q_V>9\/Q_YA M']H7KR./S'M7Z3X08S%8/Q'X5GA,15P\J^90PM;V4Y057#UH356C546E4I3M M%RA).+<8NUTFOE^,Z%*MPWFOM:<*GL\/[2GS*_)4C./+.'\LE=KF6MFULV?M M+^P=^R1\&_V+_P!FOX??"#X*>'8]#T231]#\5^+=2>>^N=3\!/!9& M01X4\.9'0\:19@C_`#U['I7X?^(?^#@S]F3PI^V)\5OV&O$7[-O[%?!M>)?$\_C31]:N?%^A M^+/%>E^!_`&G^#?#/B?Q/XJ\5>'="T>YOQ\/F^)Q&-S7,<5BZU7$8FOC<34K M5ZTY5*M6UVWHEZ'O8*E3HX/"TJ,(4J5/#THPIPBHPC%0C91B MK)+]==S][Z*_)[]E3_@JKX<^/7[7OQ&_8/\`C-^S5\>?V-_VI_!/PLTOXW^' M?AU\=)/ASJVF_%3X2ZC?6FES^+?AMX[^%WC;QQX(\42:'J5[#8ZYIFE:U>FV MO+7Q%I]I=W^J>!?B!I_A3#_;\_X*WZ#_`,$__CU^SK\!_&G[)?[2_P`5+W]J M_P`7Z%\-/@1X^^&%S\#8OA]XP^*^O:[HWAV#X:7FL>/_`(P^"KKPAXBCO_$? MA]ENO&ECX>\/ZC::E<7NC:SJ-KH?B.71_..H_7VBORG_`&M/^"G.J?LI_M!_ MLP_LUM^Q1^U)\;/B'^UQI/B"X^$'_"H]1_9_NM*N_$G@;3;;7/B;X/\`$%WX MP^-GA.3PS=_#GP_J.D:]XD\3ZW!9>`I-*U%KG1/%>K?V7K*:;]`?MS?MV_!S M]@CX6>&/B'\4]/\`'7C/Q%\2/B%X<^#WP5^#7PF\./XQ^+GQN^+_`(O%T?#/ MPZ^'OAW[786L^K:BME=SS:AK6J:1HEC#`L-QJ)U.^TG3M1'I\]OZ^?\`5F!] ML45^6OP(_P""GNA>./VJ]/\`V(OVC/V=/C/^QC^TUXP^'5U\5OA!X*^,>K_" MKQAX9^-O@K27U0>*#\-OB/\`!SQ_\0?"&I>+?!D&CWVI>*_!.HW^F^(-.T2, MZU;6]_I\-Y/:^N_MG?MY>!?V0=7^!7PWC^'GQ+^._P"T3^U%XN\1^"_V=?V> M/A#8Z`_CGXE:CX)T>U\1_$'7)=<\::]X3\">#O!/PY\-WMKX@\<^*_%GB;3; M/1-(N$O4@O(XKHVQ_5^G]?UV`^[:S-6UG2="M4OM:U/3])LI+W3--2\U.]MK M"U;4=:U*TT;1[!;B[DBA-[JVKW]CI6F6H?S[_4KVUL;5);JXAB?\Z/V;_P#@ MHM;_`!M_:9\0?L;_`!*_9A_:*_9<_:.\*_"+6?CAJOA/XP67P[U?P?J_PZTS MQ/\`#_PE:>(OA]\4?A?\0/'?@GXAZ=J>L^/[;3I)/#^H27/A[6/#OB;1?%5G MH>H0:7%J_P"8_P#P<`_MH?'7X)ZQ^P=^SUX+_9G\9^,OA[\=?^"@'[$LNK?% M.S\;_"BQM?'>M_#+X_>$_C)HWP$\`^%->\::5X@LO'/B'Q3\._"EY)XU\>)X M+^&NE6D<6G2^);MM3O;OP^+5I=P/Z8J*\A^#/C_QO\2?`6G>*_'_`,%O'G[/ M_B:[O-3MKOX9_$;7OAEXF\4Z7!8WDMM:7]WJ_P`(/'OQ(\#S6^KVZ)J%G'8> M*[R[@MYDBU*WLKQ9;:,H&E?^GY=EY_UI?^=#_@N7/$O_``4K_P""$0>:-?(_ M:NLII=SJ/*A;X^?LL!993D!(V$,I#-A<1L&M%\/:E>L=&*WMUK`\BWN=3U?4]21[^3]3/AU\*KSX?_"C3 MOA?<_%7XJ_$&]T[2=:TI?BI\0M:\/ZQ\5;S^UKS4KJVU+4=2>&LBRTK33JT>JWBWEW>_>\39IDF.X:X(RW+\?6KXW(<#F&#S&%7 M!5*%-2Q^:8C,U/#U7*?M84?K$J$[QA.3C&<(VD^7YO*\+CJ&:YYBL1AXTZ&8 M5\-6P\HUHSG;#X>GA^2I!+W93Y5).[23:;5F?R[:;=6L?_!V/KL"-Y45IYQ^QWI%VT$",P,THM+>>Y,:!G%O!+,5$<;LOZK_`/!P'9>/M2_X M(V_\%`;?X:?:&\11?`V>^U+[*SK)_P`(!IGBSPQJ7Q8WF,%OLX^%MIXQ:[7& MR2U$R3$1%R//Q_P04_9['[0?_#5P_:J_;P7]HXZJ^LGXQ)\:O`B^-OMDFAMX M7>(:F/@\-NEOX5=O"KZ&L8T5O"[-X<;3SHKM8G]I;GPCI&K>$[GP7XHA3QCH M6I^')?"_B&V\46UAJD?BK2KW2VTC5X?$=F;.'3-137+.2XCU>V-C%8W:W5S% M]D2"3R0<(M M3ORU%[-N3#A_"8W!_VJL;1A2^MYKBL?1<*\:MZ6)]FHPFDDXSBH+F>L7S M))Z,_FF_9"_X)+_`3]N#_@E?^RIHWC;]MS_@H'XM^`'Q?_90^`$NN_""R_:( M\+P_"C3H='\%^#]0N/`NG^%Y/A9>1:7HOP^\7Z#_`&/8:+)>W4FAW/AN&TDN MIYK$S-^@?[7_`(^_8F_8B_X(U^(]7^*.@-^U#^Q!$?V6?A+\,M"\.S:SI'Q M&D^._P`/=0T[P+\*/@O;MXQTU(]$UE_'.H:OX'N!\2M+6.QT[[F>7'8V MY7B/AW_P0J_9\^$GA3Q5\&/AE^U)^WMX'_9&\:>(M=U?Q#^Q5H/Q]\-P_L]2 M^'O%>HSZAXO^&>E7\_PNN/CWX9^&GC!+S4=.\6>&?"_QQT9_$6GZKJT>JW]U M^#-'\$3^&/",T?A9_"^F M^%;S2-5\#7G@M["W-EH5]X!USP[X=UOPG#_9]UHUG>Z%IUO?:1J.DK<:;M2^*G@C MX;Z%K7@K2KGPV_B/2_"7[-]WHSPZ3=^&-%N='MY%U2W_`+,OABZ'X;?#XJP( M;P1X4;()8'.@Z?R#R,'MCCTK\6/$O_!OE^RM\3_V>1^S#^T)^TG^WG^TQ\*O M#W@O2/!/P@TGXT_'_P`/7R?`.'P_]CAT#Q+\+](\"_"_P)X1O/&FA:58Q>&] M%\3?%'PQ\2;[2O"<^I^%K#[/H&MZUI^H?I+\"OV3+WX"_LXWW[.VD?M0_M0^ M/W;2+G0_#GQO^*?BCX7>*_C?X&TT>%]&$Z%;>%-6MOA%H_P^1?"EAHEK?:& M-?\`AOKZW&MW.I:OXC77[O4;IY'_`,#^O^#]^^A==U_7_#K[S\P?^""!4C_@ MM&">O_!?G_@HS@=R-WP=_'O7C_QLN+:V_P"#JS]C>&:01M>?\$I?B3:VJD,? M-G3XM_&6]:,,%;!6UL[B;(M9\>_$'P%\>?B+X`\>^$=5^*WB"YT676?B_"=)^%'A+Q1: M_$;5;'18=&UK5X_$QT_Q#IDX/B/2-7U#2?#>H:)N_M??\$N/@S^UU^T5\!?V MN'^+?[1'[.?[3'[.?A_Q3X0\`?&3]F[Q?X#\.>)KKP;XNBOX=3\)>*=.^)GP MR^*_A/7=!B36_$JVELWARVF5?$^MI=7%W'+9I9*V_5?IIO\`/0+KNOZ_X=?> M?I5\@7'`7GIGZGD<_B.*_`/_`(->;:SA_P""&?[$4D4$,4MV?VD+FZ>.-8WN M;@?M:?'>V6>=D`,TPMK:WMQ+(6<06\,6[9"BK^HNM_LAZ;J/[*5S^R?HWQ^_ M::$:9J/AN^\-ZS\=-)^)NG^(/VDM:3Q!J5[JOC36KSXH?$;PIXYCMO$7C.Z MU761J&K:1X>TR7PU;ZH]M\.D\$P:7X?31_F']E#_`().>`_V*_V3O&_[&WP! M_:T_;1\-_"CQ+<"X\':EJ7CGX+:WXY^!_P#:/B'4_$OCB#X,:]>_`,V?ANU^ M)%_J]^WBJWUW1_%$>GW5U=Z]X$'@SQ7J.J:_?&G]?U^@77=?U_PZ^\_-S_@T M3(/_``1R\%Y))7X_?'55!).U3KFEM@#.`"Q8G'4DD\FKO_!UH1_P[V^#()'' M[97@`G/0`?!']H3)/MS]/>OU!_X)K?\`!+KX/?\`!+/X=^*/A#^S]\8/VBO& MGPI\2:[+XIM/A_\`&OQ;\/O%VA>#_$UZD,.MZWX.N/#'PN\#:[IDWB*&TL%U MC3KS6-2T-YK)+^QTJQU.\U2]O^3_`&Y_^"1OP5_X*%^*+36OC_\`'/\`:G7P MOH]U;:AX9^$_@KXB>"]#^%?A;5H-$M=#N-;TCPQJ'PSUNYEUK4(+>YN+G5=8 MU;5;Z"75M7@TR;3]-OY-/'V7A_FN6Y#QAD>=9M7JT,!E>,CC*SH8>6)K5/9Q MDHTJ=)3IKFG*23E*48Q2D]79/Q.(\+B#O#,\$\$BRPSPRZ+9/'-#+ M$S)+%(C*Z.C,KHP9200:_G3$6]L?^#LGXGN88BR_P#!&C3YT+_`(170K31HVT:RO;. M\O;%KR[A74&L5L;.Q^$="_X(W_"_0/V];[_@H]:_M:_MLW/[2.KVMMX:UV:] M\=?`V3P%K?PKMM3TJ_\`^%*7_@V#]GJWMH_AC-!HFFZ?)9:=>6'BB/[,OB"U M\56_C3_BIZ^9S!T)8_&2PU5U\/+$UYT:TJ#/AC?W_`(NNI?@QHWA&;]GJY6?X:K9>._%FC?9]:U'5O%EQ;:U=ZM>^+;OQ M64\1+^LWB3PYH?B_P[KOA+Q/IEIK?AKQ/HVI^'?$&C:A$)[#5]#UJQGTS5M+ MOH6^6:TU"PN;BTN8FXDAE=#PQKCLM/Z?2^K77Y_DS>Z[K^O^'7WGXN_L!_&S M0_\`@H_^U%;_`+>>A>>WPS^#?[%7P/\`@S\.]&^WVUUIOAOX[_M:^%O`'[5_ M[4=@;*..:6'6O"_PW_X9"\&F_EOFFBNAXRTL0)'YDUU^?/\`P7Q\':3XT_X* MD?\`!O\`>'O''C7XI?##X>>*?C=^TQX`MOB9\)=63PYXO$_%;QOIOP*T?X3 M_P#"/^*+O1=?TO0_$6I^-CH5OIL]UIES>/IT6N26&QK2>ZM/WX_8)_84^!G_ M``3C_9J$?LL?L\IXJE^'GA'6/%^OQ:MXZU/2M;\:Z[K'C3Q-J/B34K_`,2: MSHVA>&[#4KFR%];>']*ECT:TDMO#>B:)I\[74UF]Y<2_MQ_L(_LZ?\%#?@=> M?`3]I'PWJFK^&$\0:5XT\(^)O"NLR^&/B%\,OB%H$=Y#X>^(?PY\5VT-Q-X= M\6Z+%J&H6MO=26M_IU[I^H:AI&LZ9JFD:A>V%P?\#S'==SXFA_X)(_LX>$/V MH/V6_P!JWXP?M?\`[8OQ<^,GP&\8>(M,_9X_X:*_:)\(^(-)?Q/X^\+ZG;>( M?"&C:8_P^\.:CKEQXC\.Z1J%]=>'M)U);V]L]"N+KRGL[&]%>2_\%@?V';_] MO#X[?L;Z'^SY^V!XU_8U_P""@?[,/ASX\?M#_LQ^--/\+:MJ_@WQ5X`U/4?@ M_P##KXWZ5JNJV$FFF*\L-4U/X1Z9JUM;ZIK=N_@[QEKNB>)_ASXR\.^+IKC0 MOM[X&?\`!-OP?\*/B3\/_BS\3OVFOVO?VQ?&OP=TW6+'X+7G[6?Q*\"^,]/^ M$U]XBT:X\->(/%WA?1?AS\+/A5I6K_$+5_"UYJ'A:;XB^/K3QGXWM/#NK:YI M6E:]I]MX@UU=1Z3]L/\`X)V_!W]M#QU\#OBKXU^('Q[^%'Q9_9KT[XH6_P`# M/BA^S[\3YOA?XU^'FK_%V\^&C>,?$MAJ$.D:O:ZS?WF@_#2#P5)H7BFQUWP) MJOA#QAXVTOQ+X0UZ?4=)O=#2OU=_/;562^6_IIV%==U_7_#K[S\(_P!BC]HG M_@K9^S-_P5"_9)_8I_X*X>"OV^%UKH6E?$*W MTOP'X1\+?&;XJ>%KW_A&]&\#6\G@?4K7X9?#^QUO0==^#_@;7]2\1R>"O$4G MBKQ/_P`(U>6K>U?\'%ZA?B#_`,$/\#'_`!N,_9;]^FMQXZYK]4/@;_P35^&W MPI_:#L_VK/B7\<_VEOVO/V@O#G@G5/AW\-/B+^U'XQ^'NO?\*<\(^))?,\8V M7PG\$_"3X6?!WX;>$=4\<1Q65CXN\5Q>#;OQ?K&DV$&BOKT>D7&I65_UW_!0 M#_@GK\#_`/@HY\*/!?PK^-6N_%'P1+\,_BQX2^-_PN^)OP4\66'@CXI_#;XG M^"H-5M=!\4^$O$6J^'_%.EV]W;VNM:C$T.I:!J=J)9+;48(8-6TW2[^SI637 M9/\`KO\`K^@[^?\`7]-?>?S:%X?\-V^FZ=I/POTKX6_#?PI MX=T_2O#6G"T\/^"_`/AS3'U.;5_$%];WGB#7M9U2^*-.[^Y?YA==_P`O+S\_ MR[G^;9\2?^"I7_!1K2_B-\0-.T[]MG]I*ST_3_&WBJRL[6W^*OBB*"UM;/7; MZWMK:")+Y4CA@@CCBA1/E5$51T!/%'_@JS_P4H[?MP_M,'CC'Q9\5`^I/_(0 M]3QUSW)&*^0/BP,_%+XE@=_'_C(?EXBU('^6,_E7GX&/KQSZ]<_USUZ]>F/] M6Z?`W!GLX7X3XL_\%)\?\GQ?M,'_NK'BOVZ M_P"G\'GICGT]/S^'.3@\CG\.!@_GW]#TH)'?CMR.N/Z<\5?^HW!?_1)<.?\` MAER[R_ZA]-D1_;&;?]#/,/\`PLQ'_P`L\E]Q^@/_``]9_P""DXS_`,9Q?M,\ M<_\`)6/%7Y#_`$\5]JWGQQ_X*W:3\&O@;\>?$?\`P4L\1>%/AY^T;:^,)?A% M>^)?VF_&.DW?B2^^'NK:?X>\L7&OW>F:+%=2BY MM]7N=,5]0'X5?AG/T_7)%?KS\;/VB?@;>?\`!.;_`()J_"OPSK7PE^)_QB_9 MLOOVJM7^(_@#Q?H?Q>-QX0F^,WQB\,>-?`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`'B[3/.N]2MSG&4JD<=1PT M;YG5AS4I4JTY^SM6<4W4I4H4Z\F\/&51.I)0?,?G_P#!C]N+_@J[\UO6M6A6.X MO?$VO>'/"6BZ386^H:SK/B?Q'HFD:=IT\]X3%]*7/Q$_X+#HO@^VT_\`X*3Z MQKFO_$GX0ZO\UL-*G$D,DGX1>+=+MM&\2Z]I5KXGT3QO;V6IW-O'X MN\._VZ-#\21"7(U;31XJT;P[XB^RWBGS8UUO0]+U`DD7-G#)E:^Z_P!N+Q-\ M*/%OP^_8;M?AQ\9?`_Q*U;X0?L@^%O@I\2-%\-Z1\2-,OO#OCBS^,'QR^)][ M'YOC/P)X5TG5M*M=*^)6C:2^J:+J-^LNM66II!'-IBVFHW'J9IPAE:S/):.7 M\/<+T\)FWMXSF^#L)B(8'V&6U<3"MB:CIP<8XC&*C25.I]6E&#]G%NL^>/+A MLSQ'U;&SKXW,75POLW%?VM5@ZKGB:=.4:<5)J3I4N:5X\ZIV-[>ZAK^E6VFPWTDLRV]>P_:G_X*Z2^#?V@? M%OB+]O#XU>`;S]F/65\/?%SP%X\^-_CCP[\1M$UV?5_^$:T[2+/PM);SS:IJ M.I^*UN?#,%E:7+3V>I65W<:U'I6CP_VFWQ)^R-KG@K0[3]I:/Q=\5?#'PKO_ M`!5^SGXE\'>!K_Q%:^.IWUKQO=^-O`7BC2],TZ;P-X2\57&G7#P>$;X)JNJ? MV5IUE=R6)FU"$.\L/W/\;_VV?@;^T_\`L2_$OQ9\2-4NO#__``4%\3V_P.^$ M_P`4DMM!U.?P[^TIX0^%'B1-1\'?':XU>RT]M-\/_$_2/"T+^"_B59ZUJ"Q> M+!I?AC7?#<5@HO\`2+?R\RR'#87B.K@\/P+PYB,DGCLAP$*]#A?"SQ&"J8NI MAIXO%59RH>SQ&7U*#Q&'JUJ:YLMQ,,/4K*="I4E2WPN,J5<`JM3.,?3Q<:.- MK>SEF=91K1HQDJ5.$5/FIUXS5.482TQ%-R44IPCSY?[,G[6?_!6C]K'Q7XG\ M%_#+]O\`^*^E^(?"O@[7_']]9^/OV@?%7A&*Y$^$M)U#7?%NLV%])-1\8Z#HGB/7HO">F^+[GP3K:Z!XGN?!?\`PEES8>%K MKQ5IVFWNCV?B#4['2[BYCN962/PC_@E!\7?A7\"/VC/&?Q&^*_Q0\!?"[15_ M9[^//@30;[X@^$/%7CO0=7\:_$OX;Z_X.\*V5]X2\-_#[XCVNLZ!!K-_;7/B MJT\1:%-HMQH27EK/9ZPTW]E7)^T#KWPD^-WPUMOB9\5_VB?V>G^)GP?^#EA\ M(?A%\#_V5O@SXU^&\/CW5)_BOXM\81^*_$EBOP*^&'P1^&^@Z#8_$C7]5URV M$P2:OXPN/#4=J-/TC6_$UWXB2\=D66T.+*^7PX/X=AD=+^P_9XI<(T<94JU ML94Q$<7A8^RP*A.G)4J*GC%B:4,L=2-;$TZU)M)T<7B*F5PQ$LUQ[QDOKG-! MYI4IJ$**I2I56I5KQ;N?LV_M;?\%8_VI+_XC:9\/_\` M@H)\5-#O?A;\.?$7Q<\5Q_$']H+Q9X2BB^'7@RRN=2\:^)K"ZF6[M;Z#PCIT M$=]K-C'.NJ?9;J.XT^QOH8+Y[.[X@_:C_P""NNG?";QI\=/"?[>_Q4^+/PF^ M&>J^%M#^)GB_X7?M':UKH^'>J>.+RXT[P7'XN\-ZK=Z#XQT_3O%>HVEWI^B> M(8/#MWX!Q\0?#'C3Q=H/BGXC?%7P;-X<\(Z-J.C>#_`OCN"?P\FH%9_%+>(+ M&+3%TAIK<1:E<3?8']:\7?M-_!OXS?\`!/K7O@7H_C7X:_LH?&#P-\0K/Q#\ M3/`GP^^%UYX>^&?[>FAZ3+JLW@;Q)?>*/`O@&_\`$6@^.?A9G^)]%LM)\4K'Q56KET*M3.,='%RH M8^<8?VG5C*=3#^S^KQ2E5]G3;O*4X5&I5:<&J+=3D3D^"/[8/_!6[X[Z!\4? M''AS]NCXX>%OAC\$=)\/:U\7OBIX]^.?BO0O!'P^M/&.M-X:\&Q:O)92ZOXC MU+4?%OB,?V)H&C^%_#OB#6+N[$LSV$.GVE[>VU'XL_MK?\%4?A'X:\$^.;K_ M`(*%_$SQ[X`^(^J^,=&\&>-/AC^TAJ_BS3-3O_`4'A2X\36FJZ2+ZQ\7^"]1 MLT\::%)%HGCSPWX8UR[M;E-3MM-DTN>SO;GR3]@WXTW'P5\*?'K6?!W[7&B? MLS_%'6[+P9H6G>"?BE\.]6^+/P#_`&@O`%U:^,Y/&GA'X@^#;/X3_%O0K?Q' MX>O8O"UQX,UWQ9XOB;^R]\,M.U/P_ M^RY=?MMV'QAUF?Q!XU_8_P#A1J7PD\#VOP$M?"4MH^B_%N#3/#O@/X7^-/BA MX@^(%Y8ZQX>USX=^&O$%CI7A#1)[._\`$6E75^VDZA=;)BZU'#U,KA6J5\14KY?2PLJ,,7+F>.PN.K4X4XK!3P:Q*+5"51JIF-3DG-5^6,*<85Y34G222I5:4)-MU%4<+(\F/_``59 M_P""DX_YOB_:8QSG_B['BO(X!Q_Q_P#Z'GGT'!_P]9_X*38X_;B_:8YZ?\79 M\5#O_P!A#UZ_ECM7Y_C.,<\<9/4GUST/Y<^E(?3\N,<\XQUQC';/8U^AK@;@ MO_HDN&]/^I+EWEVP_I^!X7]L9M_T,\P_\+,1_P#+/)'Z`#_@JS_P4GQ_R?#^ MTQG`P/\`A;/BL<9Q_P`_X`^GY4?\/6O^"DW'_&<7[2_X_%GQ5R,=_P#3SC'/ MY=:_/T-DDD=!^/OWYP>?;'J:<...>GIP".O.!G_/TH_U&X+NO^,3X<_\,N7> M7_4.ET7W!_;&;?\`0SS#_P`+,1_\L\E]Q^@!_P""K?\`P4G7_F^']I@YYY^+ M'BD]?^W\_P`_IQ17Y_DC^Z3QZ9Q['T/M17S&+X-X1CB:R7#/#R2J-)?V/@+) M>[I_NZ_J^N[7L8?-LU=&G?,L=\/_`$%U_/\`OGTO\4=.T\_$SXB,;"R)/COQ M>23:P$D_\)%J7))CR3]:X3^S--/73[$_]ND'_P`;HHK[ZE_"C_U[A_[:>(_X MD_\`'4_]*0\:9IN!_P`2^Q^\!_QZ0=,=/]7T]J7^S--^;_B7V/&_'^B0<8QC M_EG[FBBK6TO3]40MW_B?_I4!ITW3LK_H%EU3_EU@[E<_\L^_>D.F:;O;_B7V M/W2?^/2#KYG7_5]??K111+['K_[8BX?"_6/_`*0!TS3<`_V?8YW$9^R09QM/ M&?+Z>U,ATW3CNS861_>$?\>L'3?)Q_J^GMTHHI`]X^OZ,G72],W`?V=88VR' M'V2WQD%<''E]1V].U1'3--*(3I]B3D')M+?KE1G_`%?7'%%%`G\2^7Y3&G3= M.`R-/L@=Z\BU@!_U@_Z9TD6EZ9MS_9UCG8#G[);]2Q!/^KZD<'UHHIK:7I^J M*"33--!&-/L1D#.+2W&>%_Z9T]M,TT2C&GV(RR@XM+<9`5\`XCYQ@=:**GJO M1_G$F7\./^%?^E,0Z9INX?\`$OL>C?\`+I!_=B_Z9^Y_,^M2'2],RO\`Q+K' M[N?^/2WZX//^KZ\#GV'I113&]OG'\T5VTS3092-/L00D^"+2`'A1CD1]NWIV MI3ING>6I^P662%R?LL&3QGG]WSS1136TO3]4-_9_[>_]L+":7IA+@Z=8D;5X M-I;D=$[>7[G\S3?[,TW>W_$OL>0Y/^B0'HOSB6.;3- M-R?^)?9=3_RZ0?\`QND_LS3<#_B7V/4_\ND'H/\`IG115RV7]?9B*.R]%^0G G]F:;_P!`^Q_\!+?_`.-T445\GC?][K_]?/\`Y6>K2_A0_P`*/__9 ` end